Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026)

Vivos Therapeutics (VVOS) reported Short term Debt of $7.3 million for Q1 2026, down 12.62% quarter-over-quarter from $8.4 million in Q4 2025.

Vivos Therapeutics (VVOS) Short term Debt (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 5 years of Short term Debt data on file, last reported at $7.3 million in Q1 2026.

Short term Debt for Q1 2026 came in at $7.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (changed N/A YoY), and the FY2025 annual result was $8.4 million, changed N/A from the prior year.
Short term Debt fell to $7.3 million in Q1 2026 per VVOS's latest filing, from $8.4 million in the prior quarter.
Over five years, Short term Debt peaked at $8.4 million in Q4 2025 and troughed at $157000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Vivos Therapeutics	7.39 Mn	5.16 Mn	3.06 Mn

Download Data